Advisor Group Holdings Inc. Grows Stock Position in Natera, Inc. (NASDAQ:NTRA)

Advisor Group Holdings Inc. lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 23.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,293 shares of the medical research company’s stock after purchasing an additional 5,778 shares during the quarter. Advisor Group Holdings Inc.’s holdings in Natera were worth $3,376,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its stake in shares of Natera by 10.6% during the second quarter. Wells Fargo & Company MN now owns 4,047,889 shares of the medical research company’s stock worth $459,558,000 after purchasing an additional 388,979 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in Natera in the second quarter worth $10,283,000. Invesco Ltd. raised its position in Natera by 42.0% in the second quarter. Invesco Ltd. now owns 2,336,964 shares of the medical research company’s stock worth $265,316,000 after acquiring an additional 691,703 shares in the last quarter. Millennium Management LLC raised its position in Natera by 16.9% in the second quarter. Millennium Management LLC now owns 1,912,471 shares of the medical research company’s stock worth $217,123,000 after acquiring an additional 276,869 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Natera by 8.0% in the second quarter. Marshall Wace LLP now owns 1,268,144 shares of the medical research company’s stock worth $143,973,000 after acquiring an additional 94,131 shares in the last quarter. Institutional investors and hedge funds own 96.31% of the company’s stock.

NTRA opened at $67.37 on Friday. The company has a quick ratio of 5.82, a current ratio of 5.96 and a debt-to-equity ratio of 0.37. The firm has a market cap of $6.37 billion, a P/E ratio of -14.71 and a beta of 1.14. Natera, Inc. has a 52 week low of $63.91 and a 52 week high of $129.09. The business’s fifty day simple moving average is $93.34 and its 200 day simple moving average is $107.07.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 4th. The medical research company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.36). The company had revenue of $158.10 million for the quarter, compared to analyst estimates of $151.92 million. Natera had a negative net margin of 72.15% and a negative return on equity of 85.05%. The firm’s revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.72) EPS. As a group, equities analysts expect that Natera, Inc. will post -4.96 EPS for the current fiscal year.

In other Natera news, Director Herm Rosenman sold 44,503 shares of the firm’s stock in a transaction dated Monday, November 8th. The stock was sold at an average price of $29.37, for a total value of $1,307,053.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Robert Alan Schueren sold 2,116 shares of the firm’s stock in a transaction dated Monday, January 10th. The stock was sold at an average price of $74.45, for a total value of $157,536.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 163,568 shares of company stock worth $13,042,208. Corporate insiders own 10.86% of the company’s stock.

Several research analysts have issued reports on the company. Cowen assumed coverage on Natera in a research report on Friday, October 15th. They issued an “outperform” rating and a $150.00 price objective for the company. Piper Sandler assumed coverage on Natera in a research report on Thursday, January 6th. They issued an “overweight” rating and a $110.00 price objective for the company. Zacks Investment Research cut Natera from a “hold” rating to a “sell” rating in a research report on Wednesday. reiterated a “buy” rating and issued a $150.00 price objective on shares of Natera in a research report on Monday, September 27th. Finally, BTIG Research dropped their price target on Natera to $150.00 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $140.25.

Natera Profile

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

Read More: What Are Cryptocurrencies?

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.